NAGIOS: RODERIC FUNCIONANDO

Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial

dc.contributor.author	Viña Ribes, José
dc.contributor.author	Escudero, Joaquín
dc.contributor.author	Baquero, Miquel
dc.contributor.author	Cebrián, Mónica
dc.contributor.author	Carbonell Asíns, Juan Antonio
dc.contributor.author	Muñoz Cebriá, José Enrique
dc.contributor.author	Satorres Pons, Encarnación
dc.contributor.author	Meléndez Moral, Juan Carlos
dc.contributor.author	Ferrer Rebolleda, José
dc.contributor.author	Cozar Santiago, Maria del Puig
dc.contributor.author	Santabárbara Gómez, José Manuel
dc.contributor.author	Jové, Mariona
dc.contributor.author	Pamplona, Reinald
dc.contributor.author	Tarazona Santabalbina, Francisco José
dc.contributor.author	Borrás Blasco, Consuelo
dc.date.accessioned	2023-05-15T16:09:32Z
dc.date.available	2023-05-15T16:09:32Z
dc.date.issued	2022
dc.identifier.citation	Viña Ribes, José Escudero, Joaquín Baquero, Miquel Cebrián, Mónica Carbonell Asíns, Juan Antonio Muñoz Cebriá, José Enrique Satorres Pons, Encarnación Meléndez Moral, Juan Carlos Ferrer Rebolleda, José Cozar Santiago, Maria del Puig Santabárbara Gómez, José Manuel Jové, Mariona Pamplona, Reinald Tarazona Santabalbina, Francisco José Borrás Blasco, Consuelo 2022 Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial Alzheimers Research & Therapy 14 1 164
dc.identifier.uri	https://hdl.handle.net/10550/86609
dc.description.abstract	Delaying the transition from minimal cognitive impairment to Alzheimer's dementia is a major concern in Alzheimer's disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet effective substances are recommended. There is a need to develop new drugs to delay Alzheimer's dementia. We have taken a nutritional supplement approach with genistein, a chemically defined polyphenol that acts by multimodal specific mechanisms. Our group previously showed that genistein supplementation is effective to treat the double transgenic (APP/PS1) AD animal model.
dc.language.iso	eng
dc.relation.ispartof	Alzheimers Research & Therapy, 2022, vol. 14, num. 1, p. 164
dc.subject	Neurones
dc.subject	Malalties
dc.title	Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial
dc.type	journal article
dc.date.updated	2023-05-15T16:09:33Z
dc.identifier.doi	10.1186/s13195-022-01097-2
dc.identifier.idgrec	155569
dc.rights.accessRights	open access